Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Comparison of Immunohistological Staining with Different Antibodies to the c‐erbB‐2 Oncoprotein

Comparison of Immunohistological Staining with Different Antibodies to the c‐erbB‐2... Overexpression of c-erbB-2 is seen in both infiltrating and in situ mammary carcinoma. In the former it has been associated with poor prognosis. Immunohistological demonstration of membrane staining of tumor cells is considered an acceptable means of identifying c-erbB-2 protein overexpression. A variety of antibodies to the c-erbB-2 molecule are now available for this purpose. We compared the sensitivity of five of the more commonly used antibodies (Dako c-erbB-2, 21N, CB11, C Neu, and CBE1) on a series of 24 cases of in situ ductal carcinoma of the breast. The incidence of positive membrane staining in tumour cells with the different antibodies ranged from 33% (21N and CBE1) to 46% (Dako and C Neu). These antibodies were further tested on pelleted, fixed, and processed cell lines (SKBR3, MCF7, and HLB100) with a known c-erbB-2 gene copy number. Correlation between the extent and strength of staining and gene copy number was demonstrated. Titration of antibodies against known standards is particularly important when the presence of staining is interpreted as a marker of prognosis. It also permits standardisation of results and validates comparisons of studies from different laboratories. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Comparison of Immunohistological Staining with Different Antibodies to the c‐erbB‐2 Oncoprotein

Loading next page...
 
/lp/wolters-kluwer-health/comparison-of-immunohistological-staining-with-different-antibodies-to-y80VlufonO

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1062-3345
eISSN
1533-4058

Abstract

Overexpression of c-erbB-2 is seen in both infiltrating and in situ mammary carcinoma. In the former it has been associated with poor prognosis. Immunohistological demonstration of membrane staining of tumor cells is considered an acceptable means of identifying c-erbB-2 protein overexpression. A variety of antibodies to the c-erbB-2 molecule are now available for this purpose. We compared the sensitivity of five of the more commonly used antibodies (Dako c-erbB-2, 21N, CB11, C Neu, and CBE1) on a series of 24 cases of in situ ductal carcinoma of the breast. The incidence of positive membrane staining in tumour cells with the different antibodies ranged from 33% (21N and CBE1) to 46% (Dako and C Neu). These antibodies were further tested on pelleted, fixed, and processed cell lines (SKBR3, MCF7, and HLB100) with a known c-erbB-2 gene copy number. Correlation between the extent and strength of staining and gene copy number was demonstrated. Titration of antibodies against known standards is particularly important when the presence of staining is interpreted as a marker of prognosis. It also permits standardisation of results and validates comparisons of studies from different laboratories.

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 1996

There are no references for this article.